Revlimid and pomalyst specialty pharmaceuticals (fhcc)
Ended Awarded
- Contract number
- 36C25226N0208
- Awardee
-
Bristol-Myers Squibb Company UEI UFGKB2B71N12
- Awarding agency
-
Veterans Integrated Service Network 12
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $348,175
Award facts
- Contract value 100% obligated
- $348,174.87 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Lawrenceville, Lawrence Township, NJ 08648, USA
Award details come from SAM.gov/FPDS.
About this award
Bristol-Myers Squibb Company, a global biopharmaceutical manufacturer headquartered in Lawrenceville, New Jersey, received a $348,174.87 delivery order award on January 14, 2026, from Veterans Integrated Service Network 12 (VISN 12) for the supply of REVLIMID and POMALYST specialty pharmaceuticals. This firm fixed-price delivery order, with an ultimate completion date of September 30, 2026, is issued under Bristol-Myers Squibb's Federal Supply Schedule contract (36F79724D0101) for Pharmaceuticals and Drugs (FSS-61-IB) with the Department of Veterans Affairs. No set-aside designation was applied to this award. The contract represents the continuation of ongoing pharmaceutical supply agreements supporting the VA's mission to provide advanced oncology and specialized therapies to eligible veterans across the healthcare system.
This delivery order is one of more than fifty awards issued to Bristol-Myers Squibb under its GSA Schedule contract since 2022, reflecting sustained federal demand for the company's oncology and immunotherapy products. The work will be performed at Bristol-Myers Squibb's Lawrenceville, New Jersey facility, and the pharmaceutical products will support the VA's specialized treatment needs, particularly for hematologic malignancies and related conditions. The parent Federal Supply Schedule contract carries a substantial ceiling value of $12.28 billion and extends through April 30, 2029, providing the Department of Veterans Affairs with access to negotiated pharmaceutical pricing across multiple therapeutic areas.
Quick answers
Who was awarded contract 36C25226N0208?
36C25226N0208 was awarded to Bristol-Myers Squibb Company by Veterans Integrated Service Network 12 (Veterans Health Administration) on January 14, 2026.
How much is contract 36C25226N0208 worth?
The government has obligated $348,175 on 36C25226N0208.
Is contract 36C25226N0208 an order under another contract?
Yes. 36C25226N0208 is a delivery order under 36F79724D0101, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25226N0208 competed?
The extent of competition for 36C25226N0208 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award